95
Participants
Start Date
June 27, 2017
Primary Completion Date
November 22, 2018
Study Completion Date
February 14, 2019
LDV/SOF
90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
Changhua Christian Hospital, Changhua
CUB Hopital Erasme, Brussels
Cliniques Universitaires UCL Saint-Luc, Brussels
National Taiwan University Hospital, Taipei
Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino
James J. Peters VA Hospital, The Bronx
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan
Universitatsklinikum Hamburg-Eppendorf (UKE), Zentrum fur Innere Medizin - Studienambulanz Hepatol., Hamburg
Ifi Studien und Projekt GmbH an der Asklepios Klinik St. Georg, Hamburg
China Medical University Hospital, Taichung
Henry Ford Health System, Detroit
Ospedale Santa Maria Annunziata, Antella
Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt
IRCCS Ospedale Casa Sollievo Della Sofferrenza, San Giovanni Rotondo
The Liver Institute at Methodist Dallas Medical Center, Dallas
Texas Liver Institute/American Research Corporation, San Antonio
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City
Chang Gung Medical Foundation, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
University of Washington/Harborview Medical Center, Seattle
Massachusetts General Hospital, Boston
Universitätsklinikum Leipzig, Leipzig
Lead Sponsor
Gilead Sciences
INDUSTRY